Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with<sup>89</sup>Zr or<sup>211</sup>At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
The Journal of nuclear medicine